The lack of an experimentally determined structure of a target protein frequently limits the application of structure-based drug design methods. In an effort to overcome this limitation, we have investigated the use of computer model-built structures for the identification of previously unknown inhibitors of enzymes from two major protease families, serine and cysteine proteases. We have successfully used our model-built structures to identify computationally and to confirm experimentally the activity of nonpeptidic inhibitors directed against important enzymes in the schistosome [2-(4-methoxybenzoyl)-l-naphthoic acid, Ki = 3 ,uM] and malaria {oxalic bis[(2-hydroxy-1-naphthylmethylene)hydrazide], IC50 = 6 ,uM} parasite life cycles.Proteases are involved in many important biological processes including protein turnover, blood coagulation, complement activation (1), hormone processing (2), and cancer cell invasion (3). Thus, they are frequently chosen as targets for drug design and discovery. Noteworthy examples include the design of angiotensin-converting enzyme inhibitors for the treatment of hypertension (4) and programs to develop human immunodeficiency virus protease inhibitors to block proliferation of the AIDS virus (5). The critical role proteases play in the life cycle of parasitic organisms also makes them attractive drug-design targets for these infectious diseases (6).In the most simple terms, structure-based drug design methods identify favorable and unfavorable interactions between a potential inhibitor and target receptor and maximize the beneficial interactions to increase binding affinity. Obtaining an accurate structure for the receptor or ligandreceptor complex is a logical step in this process. X-ray crystallography continues to be the source of high-resolution information about protein structures. However, considerable delays often exist between determining the sequence of a protein and solving its structure. Difficulties in protein expression and more commonly in protein crystallization can delay x-ray structure determination.Currently, no general method exists for predicting tertiary structure from amino acid sequences. However, when a protein target is homologous to another protein or group of proteins of known structure, a sensible model structure can be proposed. Recent comparisons between model and crystal structures permit an assessment of the overall accuracy expected from homology model-built structures (7-9). For a sequence that is 80% identical to a protein of known structure, the expected rms deviation of the core residues is -0.6 A (10). The expected rms deviation increases to 1.8 A when the sequences are only 20% identical. However, model-built structures could still be useful in finding previously unknown lead compounds despite the uncertainties in the lower part of this range if the errors cluster far away from the enzyme active site.The proteases targeted for inhibitor design in this study are important in establishing schistosome infection or necessary for the mainten...